| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7dfb0281008cb570feea037cd350c8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbdae384a9f1ad0588422c89ddc71a00 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0225
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1207
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 |
| filingDate |
2020-01-31^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f8b1d836c38578f4b654fd87a03d97b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbdcd46ea46e68142870f3080eff21e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdfd593d881672ded42aeb867e6f37c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c69cf3563460c0b9b9290d4d5b1abc84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45f032b0c530373b8fd06a45ba316e75 |
| publicationDate |
2020-02-20^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2020200708-A1 |
| titleOfInvention |
Compositions comprising chimeric ospa molecules and methods of use thereof |
| abstract |
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis. z z z C6 Za m z H?' -* y +1 |
| priorityDate |
2012-07-27^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |